GSK adds 19,352 ordinary shares to London trading

GSK plc notified the market that 19,352 ordinary shares of 31¼ pence each were admitted to trading under existing block listing admissions connected with its Share Save Plan 2022.

Rhea-AI Filing Summary

GSK plc notified the market that 19,352 ordinary shares of 31¼ pence each were admitted to trading under existing block listing admissions connected with its Share Save Plan 2022. The admission covered August 7, 2026, through October 2, 2026, on the London Stock Exchange Main Market. The total number of securities admitted to trading following admission was 4,316,311,662, and the shares are fully fungible with existing ordinary shares.

Key Figures

Further securities admitted to trading: 19,352 shares Total securities admitted to trading: 4,316,311,662 securities Ordinary share denomination: 31¼ pence each

3 metrics

Further securities admitted to trading 19,352 shares Notification covering August 7, 2026, through October 2, 2026

Total securities admitted to trading 4,316,311,662 securities Following admission

Ordinary share denomination 31¼ pence each GSK ordinary shares

Key Terms

block listing admissions, fungibility, admitted to trading

3 terms

block listing admissions regulatory

"under existing block listing admissions of Ordinary Shares"

fungibility financial

"Fungibility: Fully fungible with existing Ordinary Shares"

admitted to trading regulatory

"securities have been admitted to trading"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GSK shares were admitted to trading?

GSK reported that 19,352 ordinary shares were admitted to trading under the notification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 10:44 AM Accepted by SEC EDGAR 10/06/2026 - 10:43 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 6 October 2026, London UK

Admission to trading

In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each (‘Ordinary Shares’) have been admitted to trading as set out in the table below. The Ordinary Shares have been admitted to trading under existing block listing admissions of Ordinary Shares in connection with the “GlaxoSmithKline plc Share Save Plan 2022”.

1a	Issuer name	GSK plc
1b	Issuer LEI	5493000HZTVUYLO1D793
2	Regulated market on which the securities have been admitted to trading	London Stock Exchange – Main Market
3	Name, type and ISIN of the securities	Ordinary Shares of 31¼ pence each ISIN: GB00BN7SWP63
4	Number of further securities admitted to trading covered by this notification	19,352
5	Total number of securities admitted to trading following admission	4,316,311,662
6	Fungibility	Fully fungible with existing Ordinary Shares
7	Date range covered by the notification	7 August 2026 – 2 October 2026
8	Prospectus information	N/A

V A Whyte

Company Secretary

6 October 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 06, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc